Compounds > technetium tc 99m hydroxymethylene diphosphonate
Page last updated: 2024-09-03

technetium tc 99m hydroxymethylene diphosphonate and Paraneoplastic Syndromes

technetium tc 99m hydroxymethylene diphosphonate has been researched along with Paraneoplastic Syndromes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bijlsma, RM; Braat, AJAT; Heerma van Voss, MR1
Giammarile, F; Lancelot, S; Tescaru, A1

Other Studies

2 other study(ies) available for technetium tc 99m hydroxymethylene diphosphonate and Paraneoplastic Syndromes

ArticleYear
    The Lancet. Oncology, 2021, Volume: 22, Issue:5

    Topics: Aged; Bone and Bones; Breast Neoplasms; Female; Humans; Hypercalcemia; Neoplasm Metastasis; Paraneoplastic Syndromes; Parathyroid Hormone-Related Protein; Technetium Tc 99m Medronate; Tomography, Emission-Computed, Single-Photon

2021
Paraneoplastic syndrome demonstrated on
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:12

    Topics: Bone Neoplasms; Hodgkin Disease; Humans; Male; Paraneoplastic Syndromes; Radiopharmaceuticals; Technetium Tc 99m Medronate; Young Adult

2016